Spots Global Cancer Trial Database for car t
Every month we try and update this database with for car t cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | NCT06197672 | Acute Myeloid L... | CD4CAR | 18 Years - | Indiana University | |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | NCT02349724 | Lung Cancer Colorectal Canc... Gastric Cancer Breast Cancer Pancreatic Canc... | Anti-CEA-CAR T | 18 Years - 80 Years | Southwest Hospital, China | |
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | NCT03373097 | Neuroblastoma Neuroblastoma R... GD2-positive So... Osteosarcoma Ewing Sarcoma Sarcoma | GD2-CART01 | 12 Months - 25 Years | Bambino Gesù Hospital and Research Institute | |
| a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies | NCT02846584 | Lymphoma, Large... Leukemia, Lymph... Lymphoma，Malign... | CD19 or CD20 CA... | 14 Years - 75 Years | Southwest Hospital, China | |
| Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | NCT04240808 | Non Hodgkin Lym... | UCD19 CAR T Cel... | 18 Years - 80 Years | University of Colorado, Denver | |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | NCT03721068 | Neuroblastoma Osteosarcoma | iC9.GD2.CAR.IL-... Cyclophosphamid... Fludarabine | 18 Months - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL | NCT02546739 | Leukemia Lymphoma | Anti-CD19-CAR | 18 Years - 70 Years | Beijing Doing Biomedical Co., Ltd. | |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | NCT06116110 | Non Hodgkin Lym... | Long-term Follo... | 18 Years - | Miltenyi Biomedicine GmbH | |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) | NCT04438083 | Renal Cell Carc... | CTX130 | 18 Years - | CRISPR Therapeutics | |
| A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | NCT02349698 | Leukemia Lymphoma | Chimeric Antige... | 4 Years - 75 Years | Southwest Hospital, China | |
| Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | NCT03170141 | Glioblastoma Mu... Glioblastoma Mu... | Antigen-specifi... | 1 Year - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL | NCT02546739 | Leukemia Lymphoma | Anti-CD19-CAR | 18 Years - 70 Years | Beijing Doing Biomedical Co., Ltd. | |
| Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release | NCT04771078 | Multiple Myelom... | Nonconforming i... | 18 Years - | Celgene | |
| A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | NCT04244656 | Multiple Myelom... | CTX120 | 18 Years - | CRISPR Therapeutics | |
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | NCT03373097 | Neuroblastoma Neuroblastoma R... GD2-positive So... Osteosarcoma Ewing Sarcoma Sarcoma | GD2-CART01 | 12 Months - 25 Years | Bambino Gesù Hospital and Research Institute | |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | NCT06197672 | Acute Myeloid L... | CD4CAR | 18 Years - | Indiana University | |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | NCT03721068 | Neuroblastoma Osteosarcoma | iC9.GD2.CAR.IL-... Cyclophosphamid... Fludarabine | 18 Months - | UNC Lineberger Comprehensive Cancer Center | |
| Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) | NCT04416984 | Relapsed or Ref... | ALLO-501A ALLO-647 Fludarabine Cyclophosphamid... | 18 Years - | Allogene Therapeutics | |
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers | NCT05035407 | Kita-kyushu Lun... | IL-2 (Aldesleuk... Cyclophosphamid... KK-LC-1 TCR Fludarabine | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | NCT05887167 | Hematologic Mal... Large B-cell Ly... Acute Lymphobla... Mantle Cell Lym... Multiple Myelom... Diffuse Large B... | autologous hema... | 18 Years - 85 Years | Cedars-Sinai Medical Center | |
| A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | NCT02349698 | Leukemia Lymphoma | Chimeric Antige... | 4 Years - 75 Years | Southwest Hospital, China | |
| CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | NCT04214886 | B-Cell Acute Ly... B-cell Lymphoma... B-cell Lymphoma... | Fludarabine Cyclophosphamid... CD19-CD34 CAR t... | 18 Years - | Loyola University | |
| CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | NCT04214886 | B-Cell Acute Ly... B-cell Lymphoma... B-cell Lymphoma... | Fludarabine Cyclophosphamid... CD19-CD34 CAR t... | 18 Years - | Loyola University | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | NCT04240808 | Non Hodgkin Lym... | UCD19 CAR T Cel... | 18 Years - 80 Years | University of Colorado, Denver | |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | NCT04502446 | T Cell Lymphoma | CTX130 | 18 Years - | CRISPR Therapeutics | |
| Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | NCT05887167 | Hematologic Mal... Large B-cell Ly... Acute Lymphobla... Mantle Cell Lym... Multiple Myelom... Diffuse Large B... | autologous hema... | 18 Years - 85 Years | Cedars-Sinai Medical Center | |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma | NCT06435910 | Multiple Myelom... | DC vaccines | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | NCT05984199 | Leukemia, Myelo... | VCAR33 | 18 Years - | Vor Biopharma | |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies | NCT04033302 | T-cell Acute Ly... T-cell Acute Ly... Acute Myeloid L... NK Cell Lymphom... | CD7-specific CA... | 6 Months - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | NCT06408194 | Leukemia Acute Lymphobla... | CD22CART infusi... Tisagenlecleuce... | 1 Year - 25 Years | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
